Cell Therapy: Actionable Takeaways from the 2023 Precision Oncology Summit Session-Reference-Cited by-同舟云学术

Cell Therapy: Actionable Takeaways from the 2023 Precision Oncology Summit Session

Published:2024-03-26 Issue:1 Volume:4 Page:
ISSN:2770-3533
Container-title:International Journal of Cancer Care and Delivery
language:en
Short-container-title:

Author:

Abrams Hannah¹^ORCID,Abuali Inas²^ORCID,Khan Abdul Moiz³^ORCID,Riano Ivy⁴^ORCID,Allen Greg⁵,Spinner Michael A⁵,Komanduri Krishna⁵

Affiliation:

1. Fred Hutchinson Cancer Center, Seattle, WA, USA

2. Mass General Cancer Center, Boston, MA, USA

3. Karmanos Cancer Institute, Detroit, MI, USA

4. Dartmouth Cancer Center, Hanover, NH, USA

5. University of California San Francisco Health, San Francisco, CA, USA

Abstract

The 2023 Precision Oncology Summit was held in San Francisco on October 7th and 8th, focusing on actionable strategies addressing personalized treatment to improve patient outcomes. This manuscript summarizes the discussion and key learning points from the “Cell Therapy” session.

Publisher

Binaytara Foundation

Reference25 articles.

1. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity;Fiona C. Thistlethwaite;Cancer Immunology, Immunotherapy,2017

2. Engineering strategies to overcome the current roadblocks in CAR T cell therapy;Sarwish Rafiq;Nature Reviews Clinical Oncology,2020

3. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies;Ruth Dannenfelser;Cell Systems,2020

4. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors;Kole T. Roybal;Cell,2016

5. Rethinking cancer targeting strategies in the era of smart cell therapeutics;Greg M. Allen;Nature Reviews Cancer,2022